Bridging haematology and cardiology: recurrent ST-segment elevation myocardial infarction in a patient with multiple myeloma Opis przypadku

##plugins.themes.bootstrap3.article.sidebar##

PDF (English)


Opublikowane: cze 25, 2026
DOI: https://doi.org/10.24292/01.OR.164010126
Słowa kluczowe:
autologous stem cell transplantation, lipoprotein(a), multiple myeloma, myocardial infarction, ST-segment elevation

##plugins.themes.bootstrap3.article.main##

Wiktoria Michnowska
Department of Cardiology and Electrotherapy, Faculty of Medicine, Medical University of Gdańsk, Poland
Aleksandra Liżewska-Springer
1. Department of Cardiology and Electrotherapy, Faculty of Medicine, Medical University of Gdańsk, Poland. 2. Cardio-Oncology Clinic, University Clinical Center, Gdańsk, Poland
Agata Tyczyńska
Department of Haematology and Transplantology, Medical University of Gdańsk, Poland
Marta Marcinkowska
I Department of Cardiology, Faculty of Medicine, Medical University of Gdańsk, Poland
Agnieszka Mickiewicz
I Department of Cardiology, Faculty of Medicine, Medical University of Gdańsk, Poland
Ewa Lewicka
1. Department of Cardiology and Electrotherapy, Faculty of Medicine, Medical University of Gdańsk, Poland. 2. Cardio-Oncology Clinic, University Clinical Center, Gdańsk, Poland

Abstrakt

We present case of a 49-year-old man with arterial hypertension, hypercholesterolemia, and nephrotic
syndrome was diagnosed with multiple myeloma, who underwent first-line treatment with the DVTd
regimen. This case highlights the complex interplay between multiple myeloma, prothrombotic anticancer
therapy, and severe dyslipoproteinemia in accelerating coronary atherosclerosis and recurrent
ischemic events.

##plugins.generic.usageStats.downloads##

##plugins.generic.usageStats.noStats##

##plugins.themes.bootstrap3.article.details##

Jak cytować
1.
Michnowska W, Liżewska-Springer A, Tyczyńska A, Marcinkowska M, Mickiewicz A, Lewicka E. Bridging haematology and cardiology: recurrent ST-segment elevation myocardial infarction in a patient with multiple myeloma. OncoReview [Internet]. 25 czerwiec 2026 [cytowane 30 czerwiec 2026];00. Dostępne na: https://www.journalsmededu.pl/index.php/OncoReview/article/view/3467
Numer
Ahead of print
Dział
CARDIO-ONCOLOGY
Creative Commons License

Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.

Copyright: ? Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

Bibliografia

1. Zangari M, Saghafifar F, Mehta P. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost. 2003; 29(3): 275-82. https://doi.org/10.1055/s-2003-40965.
2. Kronenberg F, Mora S, Stroes ESG et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022; 43(39): 3925-46. https://doi.org/10.1093/eurheartj/ehac361.
3. Nicholls SJ. PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives. Kardiol Pol. 2023; 81(2): 115-22. https://doi.org/10.33963/KP.a 2023.0030.
4. Ochotnicka J, Nowak J, Kowalski P et al. Measurement of lipoprotein(a) levels in real-world clinical and laboratory settings: A single-center experience. Pol Arch Intern Med. 2024; 134(11): 16891. https://doi.org/10.20452/pamw.16891.
5. Corso A, Lorenzi A, Terulla V et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol. 2004; 83(9): 588-591. https://doi.org/10.1007/s00277-004-0891-6.